Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Vizimpro (dacomitinib)
i
Other names:
PF-00299804, PF00299804, PF-299, PF-299804, PF-804, PF299804, PF-00299804-03
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(32)
News
Trials
Company:
Pfizer, SFJ Pharma
Drug class:
pan-HER inhibitor
Related drugs:
‹
FCN-411 (4)
Z650 (2)
CI-1033 (1)
AC480 (0)
JRF103 (0)
FCN-411 (4)
Z650 (2)
CI-1033 (1)
AC480 (0)
JRF103 (0)
›
Associations
(32)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR L861Q
Non Small Cell Lung Cancer
EGFR L861Q
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR S768I
Non Small Cell Lung Cancer
EGFR S768I
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR G719X
Non Small Cell Lung Cancer
EGFR G719X
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR G719A
Non Small Cell Lung Cancer
EGFR G719A
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C2 – Inclusion Criteria
dacomitinib
Sensitive
:
C2
dacomitinib
Sensitive: C2 – Inclusion Criteria
dacomitinib
Sensitive
:
C2
HER-2 Y772_A775dup
Non Small Cell Lung Cancer
HER-2 Y772_A775dup
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 G778_P780dup
Non Small Cell Lung Cancer
HER-2 G778_P780dup
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 A775_G776insYVMA
Non Small Cell Lung Cancer
HER-2 A775_G776insYVMA
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR A763_Y764insFQEA
Non Small Cell Lung Cancer
EGFR A763_Y764insFQEA
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 M774delinsWLV
Non Small Cell Lung Cancer
HER-2 M774delinsWLV
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 P780-Y781insGSP
Non Small Cell Lung Cancer
HER-2 P780-Y781insGSP
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 amplification
Non Small Cell Lung Cancer
HER-2 amplification
Non Small Cell Lung Cancer
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
EGFR exon 21 mutation
Non Small Cell Lung Cancer
EGFR exon 21 mutation
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR exon 19 deletion + EGFR G724S
Non Small Cell Lung Cancer
EGFR exon 19 deletion + EGFR G724S
Non Small Cell Lung Cancer
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
EGFR exon 19 deletion + EGFR K754E
Non Small Cell Lung Cancer
EGFR exon 19 deletion + EGFR K754E
Non Small Cell Lung Cancer
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
EGFR L858R + EGFR E709X
Non Small Cell Lung Cancer
EGFR L858R + EGFR E709X
Non Small Cell Lung Cancer
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
dacomitinib
Resistant: C3 – Early Trials
dacomitinib
Resistant
:
C3
EGFR D770 delinsGY
Non Small Cell Lung Cancer
EGFR D770 delinsGY
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR exon 18 deletion
Non Small Cell Lung Cancer
EGFR exon 18 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR L747P
Non Small Cell Lung Cancer
EGFR L747P
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR exon 21 mutation + EGFR L858R
Non Small Cell Lung Cancer
EGFR exon 21 mutation + EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
EGFR G719A + EGFR I706T
Non Small Cell Lung Cancer
EGFR G719A + EGFR I706T
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
EGFR L858R
Lung Adenocarcinoma
EGFR L858R
Lung Adenocarcinoma
bevacizumab + dacomitinib
Sensitive: C4 – Case Studies
bevacizumab + dacomitinib
Sensitive
:
C4
bevacizumab + dacomitinib
Sensitive: C4 – Case Studies
bevacizumab + dacomitinib
Sensitive
:
C4
EGFR L858R + TP53 R273C + HER-2 S442L
Lung Adenocarcinoma
EGFR L858R + TP53 R273C + HER-2 S442L
Lung Adenocarcinoma
olaparib + anlotinib + dacomitinib
Sensitive: C4 – Case Studies
olaparib + anlotinib + dacomitinib
Sensitive
:
C4
olaparib + anlotinib + dacomitinib
Sensitive: C4 – Case Studies
olaparib + anlotinib + dacomitinib
Sensitive
:
C4
EGFR exon 19 deletion + EGFR G724S
Lung Cancer
EGFR exon 19 deletion + EGFR G724S
Lung Cancer
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
EGFR exon 21 mutation
Lung Adenocarcinoma
EGFR exon 21 mutation
Lung Adenocarcinoma
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
dacomitinib
Sensitive: C4 – Case Studies
dacomitinib
Sensitive
:
C4
KRAS mutation
Lung Adenocarcinoma
KRAS mutation
Lung Adenocarcinoma
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
EGFR exon 19 deletion + EGFR L861Q
Lung Adenocarcinoma
EGFR exon 19 deletion + EGFR L861Q
Lung Adenocarcinoma
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
EGFR L861Q
Lung Adenocarcinoma
EGFR L861Q
Lung Adenocarcinoma
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
dacomitinib
Sensitive: D – Preclinical
dacomitinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login